Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2011 1
2012 1
2013 1
2014 1
2015 1
2016 1
2018 1
2019 4
2020 1
2021 3
2022 2
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Global Variations in Heart Failure Etiology, Management, and Outcomes.
G-CHF Investigators; Joseph P, Roy A, Lonn E, Störk S, Floras J, Mielniczuk L, Rouleau JL, Zhu J, Dzudie A, Balasubramanian K, Karaye K, AlHabib KF, Gómez-Mesa JE, Branch KR, Makubi A, Budaj A, Avezum A, Wittlinger T, Ertl G, Mondo C, Pogosova N, Maggioni AP, Orlandini A, Parkhomenko A, ElSayed A, López-Jaramillo P, Grinvalds A, Temizhan A, Hage C, Lund LH, Kazmi K, Lanas F, Sharma SK, Fox K, McMurray JJV, Leong D, Dokainish H, Khetan A, Yonga G, Kragholm K, Wagdy Shaker K, Mwita JC, Al-Mulla AA, Alla F, Damasceno A, Silva-Cardoso J, Dans AL, Sliwa K, O'Donnell M, Bazargani N, Bayés-Genís A, McCready T, Probstfield J, Yusuf S. G-CHF Investigators, et al. JAMA. 2023 May 16;329(19):1650-1661. doi: 10.1001/jama.2023.5942. JAMA. 2023. PMID: 37191704 Free PMC article.
The proportion of participants with HF with reduced ejection fraction taking the combination of a beta-blocker, renin-angiotensin system inhibitor, and mineralocorticoid receptor antagonist was highest in upper-middle-income (61.9%) and high-income countries (51.1%), and it was l …
The proportion of participants with HF with reduced ejection fraction taking the combination of a beta-blocker, renin-angiotensin system inh …
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sørensen T, Böhm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlström U, Echeverria LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Li J, Lund M, Macdonald P, Mareev V, Momomura SI, O'Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Varin C, Honarpour N, Abbasi SA, Malik FI, Kurtz CE; GALACTIC-HF Investigators. Teerlink JR, et al. N Engl J Med. 2021 Jan 14;384(2):105-116. doi: 10.1056/NEJMoa2025797. Epub 2020 Nov 13. N Engl J Med. 2021. PMID: 33185990 Clinical Trial.
At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and …
At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil …
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
At week 78, the between-group differences in the change from baseline in the ADAS-cog11 and DAD scores (bapineuzumab group minus placebo group) were -0.2 (P=0.80) and -1.2 (P=0.34), respectively, in the carrier study; the corresponding differences in the noncarrier study were -0. …
At week 78, the between-group differences in the change from baseline in the ADAS-cog11 and DAD scores (bapineuzumab group minus placebo gro …
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1.
Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, Abeliovich H, Abildgaard MH, Abudu YP, Acevedo-Arozena A, Adamopoulos IE, Adeli K, Adolph TE, Adornetto A, Aflaki E, Agam G, Agarwal A, Aggarwal BB, Agnello M, Agostinis P, Agrewala JN, Agrotis A, Aguilar PV, Ahmad ST, Ahmed ZM, Ahumada-Castro U, Aits S, Aizawa S, Akkoc Y, Akoumianaki T, Akpinar HA, Al-Abd AM, Al-Akra L, Al-Gharaibeh A, Alaoui-Jamali MA, Alberti S, Alcocer-Gómez E, Alessandri C, Ali M, Alim Al-Bari MA, Aliwaini S, Alizadeh J, Almacellas E, Almasan A, Alonso A, Alonso GD, Altan-Bonnet N, Altieri DC, Álvarez ÉMC, Alves S, Alves da Costa C, Alzaharna MM, Amadio M, Amantini C, Amaral C, Ambrosio S, Amer AO, Ammanathan V, An Z, Andersen SU, Andrabi SA, Andrade-Silva M, Andres AM, Angelini S, Ann D, Anozie UC, Ansari MY, Antas P, Antebi A, Antón Z, Anwar T, Apetoh L, Apostolova N, Araki T, Araki Y, Arasaki K, Araújo WL, Araya J, Arden C, Arévalo MA, Arguelles S, Arias E, Arikkath J, Arimoto H, Ariosa AR, Armstrong-James D, Arnauné-Pelloquin L, Aroca A, Arroyo DS, Arsov I, Artero R, Asaro DML, Aschner M, Ashrafizadeh M, Ashur-Fabian O, Atanasov AG, Au AK, Auberger P, Auner HW, Aurelian L, Autelli R… See abstract for full author list ➔ Klionsky DJ, et al. Autophagy. 2021 Jan;17(1):1-382. doi: 10.1080/15548627.2020.1797280. Epub 2021 Feb 8. Autophagy. 2021. PMID: 33634751 Free PMC article.
Global economic burden of unmet surgical need for appendicitis.
Reuter A, Rogge L, Monahan M, Kachapila M, Morton DG, Davies J, Vollmer S; NIHR Global Surgery Collaboration. Reuter A, et al. Br J Surg. 2022 Sep 9;109(10):995-1003. doi: 10.1093/bjs/znac195. Br J Surg. 2022. PMID: 35881506 Free PMC article.
A human capital approach was applied, focusing on the economic burden resulting from premature death and absenteeism. RESULTS: Excess mortality was 4185 per 100 000 cases of appendicitis using approach 1 and 3448 per 100 000 using approach 2. ...The largest share of …
A human capital approach was applied, focusing on the economic burden resulting from premature death and absenteeism. RESULTS: Excess mortal …
Pooled analysis of WHO Surgical Safety Checklist use and mortality after emergency laparotomy.
GlobalSurg Collaborative. GlobalSurg Collaborative. Br J Surg. 2019 Jan;106(2):e103-e112. doi: 10.1002/bjs.11051. Br J Surg. 2019. PMID: 30620059 Free PMC article.
After adjusting for patient and disease factors, checklist use before emergency laparotomy was more common in countries with a high Human Development Index (HDI) (2455 of 2741, 89.6 per cent) compared with that in countries with a middle (753 of 1242, 60.6 per cent; …
After adjusting for patient and disease factors, checklist use before emergency laparotomy was more common in countries with a high Human De …
Global variation in anastomosis and end colostomy formation following left-sided colorectal resection.
GlobalSurg Collaborative. GlobalSurg Collaborative. BJS Open. 2019 Feb 28;3(3):403-414. doi: 10.1002/bjs5.50138. eCollection 2019 Jun. BJS Open. 2019. PMID: 31891112 Free PMC article.
RESULTS: In total, 1635 patients from 242 hospitals in 57 countries undergoing left-sided colorectal resection were included: 113 (6.9 per cent) from low-HDI, 254 (15.5 per cent) from middle-HDI and 1268 (77.6 per cent) from high-HDI countries. There was a hi …
RESULTS: In total, 1635 patients from 242 hospitals in 57 countries undergoing left-sided colorectal resection were included: 113 (6.9 pe …
A Comparison of In Vitro Points of Departure with Human Blood Levels for Per- and Polyfluoroalkyl Substances (PFAS).
Judson RS, Smith D, DeVito M, Wambaugh JF, Wetmore BA, Paul Friedman K, Patlewicz G, Thomas RS, Sayre RR, Olker JH, Degitz S, Padilla S, Harrill JA, Shafer T, Carstens KE. Judson RS, et al. Toxics. 2024 Apr 5;12(4):271. doi: 10.3390/toxics12040271. Toxics. 2024. PMID: 38668494 Free PMC article.
Per- and polyfluoroalkyl substances (PFAS) are widely used, and their fluorinated state contributes to unique uses and stability but also long half-lives in the environment and humans. ...The result is a Bioactive Concentration to Blood Concentration Ratio (BCBCR), similar …
Per- and polyfluoroalkyl substances (PFAS) are widely used, and their fluorinated state contributes to unique uses and stability but …
Observation of τ Lepton Pair Production in Ultraperipheral Pb-Pb Collisions at sqrt[s_{NN}]=5.02  TeV.
Tumasyan A, Adam W, Andrejkovic JW, Bergauer T, Chatterjee S, Damanakis K, Dragicevic M, Escalante Del Valle A, Hussain PS, Jeitler M, Krammer N, Lechner L, Liko D, Mikulec I, Paulitsch P, Pitters FM, Schieck J, Schöfbeck R, Schwarz D, Templ S, Waltenberger W, Wulz CE, Darwish MR, Janssen T, Kello T, Rejeb Sfar H, Van Mechelen P, Bols ES, D'Hondt J, De Moor A, Delcourt M, El Faham H, Lowette S, Moortgat S, Morton A, Müller D, Sahasransu AR, Tavernier S, Van Doninck W, Vannerom D, Clerbaux B, De Lentdecker G, Favart L, Hohov D, Jaramillo J, Lee K, Mahdavikhorrami M, Makarenko I, Malara A, Paredes S, Pétré L, Postiau N, Starling E, Thomas L, Vanden Bemden M, Vander Velde C, Vanlaer P, Dobur D, Knolle J, Lambrecht L, Mestdach G, Niedziela M, Rendón C, Roskas C, Samalan A, Skovpen K, Tytgat M, Van Den Bossche N, Vermassen B, Wezenbeek L, Benecke A, Bruno G, Bury F, Caputo C, David P, Delaere C, Donertas IS, Giammanco A, Jaffel K, Jain S, Lemaitre V, Mondal K, Prisciandaro J, Taliercio A, Tran TT, Vischia P, Wertz S, Alves GA, Coelho E, Hensel C, Moraes A, Rebello Teles P, Aldá Júnior WL, Alves Gallo Pereira M, Barroso Ferreira Filho M, Brandao Malbouisson H, Carvalho W, Chinellato J, … See abstract for full author list ➔ Tumasyan A, et al. Phys Rev Lett. 2023 Oct 13;131(15):151803. doi: 10.1103/PhysRevLett.131.151803. Phys Rev Lett. 2023. PMID: 37897747
The measurement is based on a data sample with an integrated luminosity of 404 mub^{-1} collected by the CMS experiment at a center-of-mass energy per nucleon pair of sqrt[s_{NN}]=5.02 TeV. The gammagammatau^{+}tau^{-} process is observed for tau^{+}tau^{-} events with a m …
The measurement is based on a data sample with an integrated luminosity of 404 mub^{-1} collected by the CMS experiment at a center-of-mass …
Comparative measurement and quantitative risk assessment of alcohol consumption through wastewater-based epidemiology: An international study in 20 cities.
Ryu Y, Barceló D, Barron LP, Bijlsma L, Castiglioni S, de Voogt P, Emke E, Hernández F, Lai FY, Lopes A, de Alda ML, Mastroianni N, Munro K, O'Brien J, Ort C, Plósz BG, Reid MJ, Yargeau V, Thomas KV. Ryu Y, et al. Sci Total Environ. 2016 Sep 15;565:977-983. doi: 10.1016/j.scitotenv.2016.04.138. Epub 2016 May 14. Sci Total Environ. 2016. PMID: 27188267 Free article.
For each sample a specific and stable alcohol consumption biomarker, ethyl sulfate (EtS) was determined by liquid chromatography coupled to tandem mass spectrometry. The EtS concentrations were used for estimation of per capita alcohol consumption in each city, which was f …
For each sample a specific and stable alcohol consumption biomarker, ethyl sulfate (EtS) was determined by liquid chromatography coupled to …
24 results